| Carol Ann Donahue, DPM | |
|
575 N Sioux Point Rd, Dakota Dunes, SD 57049-5312 | |
| (605) 217-2667 | |
| (605) 217-2900 |
| Full Name | Carol Ann Donahue |
|---|---|
| Gender | Female |
| Speciality | Podiatry |
| Experience | 22 Years |
| Location | 575 N Sioux Point Rd, Dakota Dunes, South Dakota |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1215939392 | NPI | - | NPPES |
| 1215939392 | Medicaid | SD | |
| 1215939392 | Medicaid | IA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 213E00000X | Podiatrist | 180 (South Dakota) | Primary |
| 213E00000X | Podiatrist | 00781 (Iowa) | Secondary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Cnos Pc | 4284548942 | 102 |
| Cnos Pc | 4284548942 | 102 |
News Archive
A new study has found that taking probiotics could drastically reduce the response of cancer patients to immunotherapy. Patients on a fiber-rich diet showed a five-fold increase in response.
A recent large German study has shown that a new combination therapy for breast cancer treatment leads to a lowered risk of the disease coming back. A commentary on this landmark clinical trial has been published in the latest issue of the Journal of Clinical Oncology by the researchers Masey Ross and Charles Geyer Jr. from the VCU Massey Cancer Center. The commentary was titled, "Nab-Paclitaxel: A New Standard of Care in Neoadjuvant Therapy of High-Risk Early Breast Cancer?"
The Ensign Group, Inc., the parent company of the Ensign™ group of skilled nursing, rehabilitative care services and assisted living companies, today announced that its Board of Directors has declared a quarterly cash dividend of $0.055 per share of Ensign common stock, payable on or before January 31, 2011 to shareholders of record as of December 31, 2010.
By launching Sona, the Sonova Group is introducing a novel business concept combining a specialized product portfolio with easy fitting and simplified logistic processes, which are unique in the industry. The new brand broadens the portfolio of the established hearing solutions of Phonak and Unitron and is aimed at the market segment for mild-to-moderate hearing loss. It features mainly the integrated service concept providing audiologists with new opportunities to make their hearing solutions more accessible to consumers.
A combination of two targeted cancer drugs showed unprecedented, "clinically meaningful" activity in patients with highly malignant brain tumors that carried a rare genetic mutation, according to a clinical trial report by investigators from Dana-Farber Cancer Institute.
› Verified 2 days ago
| Provider Name | Cnos Pc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1881604320 PECOS PAC ID: 4284548942 Enrollment ID: O20031217000907 |
News Archive
A new study has found that taking probiotics could drastically reduce the response of cancer patients to immunotherapy. Patients on a fiber-rich diet showed a five-fold increase in response.
A recent large German study has shown that a new combination therapy for breast cancer treatment leads to a lowered risk of the disease coming back. A commentary on this landmark clinical trial has been published in the latest issue of the Journal of Clinical Oncology by the researchers Masey Ross and Charles Geyer Jr. from the VCU Massey Cancer Center. The commentary was titled, "Nab-Paclitaxel: A New Standard of Care in Neoadjuvant Therapy of High-Risk Early Breast Cancer?"
The Ensign Group, Inc., the parent company of the Ensign™ group of skilled nursing, rehabilitative care services and assisted living companies, today announced that its Board of Directors has declared a quarterly cash dividend of $0.055 per share of Ensign common stock, payable on or before January 31, 2011 to shareholders of record as of December 31, 2010.
By launching Sona, the Sonova Group is introducing a novel business concept combining a specialized product portfolio with easy fitting and simplified logistic processes, which are unique in the industry. The new brand broadens the portfolio of the established hearing solutions of Phonak and Unitron and is aimed at the market segment for mild-to-moderate hearing loss. It features mainly the integrated service concept providing audiologists with new opportunities to make their hearing solutions more accessible to consumers.
A combination of two targeted cancer drugs showed unprecedented, "clinically meaningful" activity in patients with highly malignant brain tumors that carried a rare genetic mutation, according to a clinical trial report by investigators from Dana-Farber Cancer Institute.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Carol Ann Donahue, DPM 575 N Sioux Point Rd, Dakota Dunes, SD 57049-5312 Ph: (605) 217-2667 | Carol Ann Donahue, DPM 575 N Sioux Point Rd, Dakota Dunes, SD 57049-5312 Ph: (605) 217-2667 |
News Archive
A new study has found that taking probiotics could drastically reduce the response of cancer patients to immunotherapy. Patients on a fiber-rich diet showed a five-fold increase in response.
A recent large German study has shown that a new combination therapy for breast cancer treatment leads to a lowered risk of the disease coming back. A commentary on this landmark clinical trial has been published in the latest issue of the Journal of Clinical Oncology by the researchers Masey Ross and Charles Geyer Jr. from the VCU Massey Cancer Center. The commentary was titled, "Nab-Paclitaxel: A New Standard of Care in Neoadjuvant Therapy of High-Risk Early Breast Cancer?"
The Ensign Group, Inc., the parent company of the Ensign™ group of skilled nursing, rehabilitative care services and assisted living companies, today announced that its Board of Directors has declared a quarterly cash dividend of $0.055 per share of Ensign common stock, payable on or before January 31, 2011 to shareholders of record as of December 31, 2010.
By launching Sona, the Sonova Group is introducing a novel business concept combining a specialized product portfolio with easy fitting and simplified logistic processes, which are unique in the industry. The new brand broadens the portfolio of the established hearing solutions of Phonak and Unitron and is aimed at the market segment for mild-to-moderate hearing loss. It features mainly the integrated service concept providing audiologists with new opportunities to make their hearing solutions more accessible to consumers.
A combination of two targeted cancer drugs showed unprecedented, "clinically meaningful" activity in patients with highly malignant brain tumors that carried a rare genetic mutation, according to a clinical trial report by investigators from Dana-Farber Cancer Institute.
› Verified 2 days ago
Dr. David Rettedal, DPM Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 575 N Sioux Point Rd, Dakota Dunes, SD 57049 Phone: 605-217-2667 Fax: 605-217-2900 |